Characteristics | n/N | % | |
---|---|---|---|
Age | Mean 56.6 y (range, 21–86 y) | ||
FIGO stage | |||
III | 277/301 | 92.0% | |
IV | 24/301 | 8.0% | |
Histology | |||
Serous | 148/301 | 49.2% | |
Undifferentiated | 116/301 | 38.5% | |
Endometrioid | 17/301 | 5.6% | |
Mucinous | 15/301 | 5.0% | |
Others | 5/301 | 1.7% | |
Tumor grade | |||
G1 | 27/301 | 9.0% | |
G2 | 66/301 | 21.9% | |
G3 | 208/301 | 69.1% | |
Ascites > 500 ml | 62/301 | 20.6% | |
Primary Cytoreductive Surgery | 240/301 | 79.7% | |
Interval Debulking Surgery | 61/301 | 20.3% | |
Residual Disease after surgery | |||
R0 | 209/301 | 69.4% | |
R < 0.5 | 35/301 | 11.6% | |
R2 | 57/301 | 19% | |
R0 in G3 | 130/208 | 62.5% | |
R0 in G1-2 | 79/93 | 84.9% |